VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

4.33

+0.03 (+0.70%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	4.30
Open	4.33
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	4.25 - 4.39
52 Week Range	1.78 - 5.71
Volume	854,080
Avg. Volume	820,483

Market Cap	220.691M
Beta	3.46
PE Ratio (TTM)	N/A
EPS (TTM)	-1.76
Earnings Date	May 8, 2018 - May 14, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.67

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire2 days ago
Verastem to Host Analyst and Investor Day on May 2, 2018
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it will host an Analyst and Investor Day titled, “Duvelisib: Harnessing the Power of Dual PI3K Inhibition,” on Wednesday, May 2, 2018 from 10:30 am – 1:00 pm ET in New York City.
GlobeNewswire6 days ago
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Zacks12 days ago
Verastem (VSTM) in Focus: Stock Moves 8% Higher
Shares of Verastem (VSTM) rose nearly 8% yesterday.
Business Wire16 days ago
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 364,000 shares of Verastem’s common stock.
CNBC16 days ago
Biotech shares soar on dealmaking, drug breakthroughs; AveXis jumps 77 percent
AveXis shares led the biotech sector higher on Monday after Novartis announced its plans to buy the gene therapy company.
Benzinga16 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Verastem Inc (NASDAQ: VSTM ) stock gained more than ...
Business Wire16 days ago
FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S.
Business Wire27 days ago
Verastem to Present at the H.C. Wainwright Global Life Sciences Conference
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C.
Zackslast month
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.
Business Wirelast month
Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer & Co.
Business Wirelast month
Verastem to Present at Upcoming Conferences
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will
Business Wirelast month
Verastem Reports Year-End 2017 Financial Results
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and provided an overview of certain corporate developments and plans.
Business Wire2 months ago
Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eight new employees to purchase an aggregate of 114,000 shares of Verastem’s common stock.
Business Wire2 months ago
Verastem to Present at the 30th Annual ROTH Conference
Verastem, Inc. , focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30th Annual ROTH Conference on Monday, March 12, 2018 at 4:30 pm PST in Dana Point, CA, USA.
GlobeNewswire2 months ago
Research Report Identifies Ichor, TASER International, Premier, NuVasive, Verastem, and BLACKLINE INC with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ichor ...
ACCESSWIRE2 months ago
Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma
Stock Monitor: Cambrex Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on Verastem, Inc. (NASDAQ: VSTM). If you want ...
Benzinga3 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock traded higher by 0.8 ...
Business Wire3 months ago
Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application to the U.S.
Business Wire3 months ago
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 219,000 shares of Verastem’s common stock.
Business Wire3 months ago
Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno-Oncology Symposium being held January 25-27, ...
Business Wire4 months ago
Verastem Announces Increased Hercules Debt Facility
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with Hercules Capital, Inc., increasing its existing borrowing limit under the loan facility from $25 million to up to $50 million in financing.
Business Wire4 months ago
Verastem Appoints Joseph Lobacki as Chief Commercial Officer
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and Chief Commercial Officer.
Business Wire4 months ago
Verastem Announces Pricing of Public Offering of Common Stock
Verastem, Inc., , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its previously announced underwritten public offering of approximately $25 million of shares of its common stock.
InvestorPlace4 months ago
3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM)
The afternoon was a busy one with several companies announcing changes in their structure and hierarchy, including DDR Corp (NYSE:DDR), Hess Corp. (NYSE:HES) and Verastem Inc (NASDAQ:VSTM). Hess executives have yet to comment on the matter.
Business Wire4 months ago
Verastem Announces Public Offering of Common Stock
Verastem, Inc., , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in an underwritten public offering.